Navigation Links
eltrombopag in Medical News

Novel therapeutic approaches may improve patient outcomes in several platelet disorders

...l transfusions were the same in both arms. Oral eltrombopag for the Long-Term Treatment of Patients With Chron... multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significan...icroliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patien...

PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL

...ewed studies evaluating the safety and efficacy of eltrombopag in the short-term setting. Clinical data were presented and discussed that support eltrombopag increased platelet counts and reduced bleeding. ...ne Development Center at GSK. "An FDA approval for eltrombopag would represent an important development for these...

GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder

...s an increased risk of bruising and bleeding.(1,2) eltrombopag is an investigational, once-daily oral treatment t...it a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008. About the Data Submitted ...enna, Austria. At the end of the trial, 59% of eltrombopag treated patients on the 50mg dose and 16% of place...

Eltrombopag studied in Idiopathic Thrombocytopenic Purpura

...investigational oral platelet growth factor called eltrombopag successfully increased platelet counts and decreas...ind for ITP patients, the Phase 2 study found that eltrombopag doses of 50 and 75 mg daily elevated platelet coun... of adverse effects was similar in the placebo and eltrombopag treated groups. "These findings represent an im...

Drug May Help Reverse Clotting Deficiency

... eltrombopag might also aid patients with hepatitis liver disea... begin antiviral therapy for their condition after eltrombopag raised their platelet counts. "Eltrombopag is ...ly bleeding and bruising," Schwartz explained. eltrombopag is thought to stimulate megakaryocytes, the bone m...

GSK’s New Anticancer Drug A Huge Success In Drug trail

...y small, is likely to be transformed next year with the launch of Tykerb and other blockbuster drugs, such as the cervical cancer vaccine Cervarix and eltrombopag that is a blood-clotting agent in the treatment of breast cancer. They are also developing a lung cancer vaccine that would stop the disease from spre...
eltrombopag in Medical Technology

Novel Therapeutic Approaches May Transform Treatment and Improve Patient Outcomes in Several Platelet Disorders

...fusions were the same in both arms. Oral eltrombopag for the Long-Term Treatment of Patients With Chron... multicenter, phase III study found that long-term eltrombopag therapy compared with placebo treatment significan...icroliters. They were randomized to receive either eltrombopag at a starting dose of 50 mg once daily (135 patien...

GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP

...hKline. GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008. Important Safety Information BOXED WARNI... to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration o...

FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder

... GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008; the proposed trade name ... to therapy with PROMACTA. Cataracts were observed in toxicology studies of eltrombopag in rodents. Perform a baseline ocular examination prior to administration o...

GSK Update on FDA Review of Promacta(R) (Eltrombopag)

...May 30, the Oncology Drugs Advisory Committee unanimously voted, 16-0, that eltrombopag demonstrated a favorable risk-benefit profile for the short-term treatment ...pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, common cold, and nausea. About GlaxoSmithKline GlaxoSmit...

FDA Grants Priority Review for PROMACTA(R) (eltrombopag)

...it a Marketing Authorization Application (MAA) for eltrombopag in the treatment of chronic ITP in Europe in 2008 ...se are rare.(1) About PROMACTA (eltrombopag) eltrombopag is an oral, non-peptide thrombopoietin receptor ag...ne marrow cells that give rise to blood platelets. eltrombopag was discovered as a result of research collaborati...

Long-Term Safety and Efficacy Data on Promacta(TM) (Eltrombopag) Presented at American Society of Hematology Annual Meeting

...iries: Frank Murdolo 215-751-7002 Tom Curry 215-751-5419 REFERENCES (1) Bussel, JB., Cheng, G., et al. Long-term safety and efficacy of oral eltrombopag for the treatment of subjects with idiopathic thrombocytopenic purpura (ITP): preliminary data from the EXTEND study. Blood. 2007; 110 (11). Published...

Pivotal Phase III Trial Showed Promacta (eltrombopag olamine) Raised Platelet Counts and Reduced Bleeding in Patients With Chronic ITP

...189 patients across 135 centers in 26 countries. REPEAT (Repeat ExPosure to eltrombopag in Adults with Idiopathic Thrombocytopenic Purpura) will involve 50 patient...51 5419 REFERENCES (1) Bussel, J., Provan A., Shamsi T et al. eltrombopag Raises Platelet Count and Reduces Bleeding compared with Placebo ...
eltrombopag in Biological News

Lancet study supports new, highly effective treatment for blood disorder

...ed late 2007 in the New England Journal of Medicine. This trial showed that eltrombopag was effective in raising platelet counts and lowering bleeding in adult sub...cts. Ongoing and future studies will evaluate the safety and efficacy of eltrombopag as a long-term treatment for ITP, and its efficacy and safety in population...

Eltrombopag effective for hepatitis C patients with low blood-platelet counts

...the door to effective treatment. "In this study, eltrombopag increased platelet counts in a dose-dependent mann...common reason for a liver transplant. With other eltrombopag findings, NewYork-Presbyterian/Weill Cornell's Dr.... GlaxoSmithKline, which is developing eltrombopag. eltrombopag (marketed as Promacta in the U.S. and Revolade in ...
Other Tags
(Date:11/24/2014)... 24, 2014 Volpara Solutions announced ... at the 100th Annual Meeting of the Radiology ... 2014 (RSNA Booth 1752 – South Hall). Volpara ... and the rest of its innovative suite of ... which enable personalized measurements of volumetric density, patient-specific ...
(Date:11/24/2014)... SweetDressy.com, a well-known dress supplier and leader in the ... Dresses. All these fresh items are offered at affordable ... special offer is valid until Dec. 20, 2014. Click ... working well in the fashion industry for years. They ... dresses may be the best products for many ladies ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... Vancouver, BC (PRWEB) November 23, 2014 Pro ... recently announced that it will now be providing an 8 ... number of hot water tank installations went up due to ... Care to assure its customers of the premium service that ... be offering 8 year warranty on John Wood and Bradford ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
(Date:11/3/2014)... Research and Markets has announced the ... Markets and Companies" to their offering. ... which have already started to play an important role in ... the old fashioned bone marrow transplants. Role of cells in ... become a part of medical practice. Stem cells ...
(Date:11/3/2014)...  NeuroSigma ® , Inc. (NeuroSigma), a ... on commercialization of its non-invasive Monarch ... neurological and neuropsychiatric disorders, announced today that the ... Notice of Allowance for Mexican Patent Application No. ... and the Regents of the University of California ...
(Date:11/2/2014)... of Physics World , James Dacey explores the ... death" to take their innovations from the lab into ... challenge facing all start-up companies as they move from ... of two main factors: physics-based inventions are usually far ... out to be a lot more complicated than had ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3The 'valley of death' facing physics start-ups 2
Other Contents